

**ARTICLE 33-06
REPORTABLE CONDITIONS**

| | |
|------------|---|
| Chapter | |
| 33-06-01 | Conditions Designated as Reportable |
| 33-06-02 | Reporting |
| 33-06-03 | Health Officer Investigation |
| 33-06-04 | Control of Specific Diseases |
| 33-06-05 | School Immunization Requirements |
| 33-06-05.1 | General Provisions |
| 33-06-05.2 | Students With Significant Contagious Diseases |
| 33-06-05.3 | Employees With Significant Contagious Diseases |
| 33-06-05.4 | Treatment of Independent Contractors With Significant Contagious Diseases |
| 33-06-05.5 | Relations With the Public |
| 33-06-05.6 | Education |
| 33-06-06 | Food Handlers [Repealed] |
| 33-06-07 | Laboratory Specimens for Carriers of Disease |
| 33-06-08 | Isolation Requirements |
| 33-06-09 | Common Carriers Federal Regulation Adopted and Shipment of Birds of the Psittacine Family |
| 33-06-10 | Disinfection |
| 33-06-11 | [Reserved] |
| 33-06-12 | [Reserved] |
| 33-06-13 | [Reserved] |
| 33-06-14 | [Reserved] |
| 33-06-15 | Preparation of Bodies and Transportation |
| 33-06-16 | Newborn Screening Program |

**CHAPTER 33-06-01
CONDITIONS DESIGNATED AS REPORTABLE**

| | |
|-------------|-----------------------|
| Section | |
| 33-06-01-01 | Reportable Conditions |

33-06-01-01. Reportable conditions.

All reports and information concerning reportable conditions are confidential and not open to inspection. The following designated reportable conditions must be reported to the state department of health by the persons designated in chapter 33-06-02. If any reportable condition is designated by an asterisk, an appropriate sample or isolate must be submitted to the division of microbiology (public health laboratory) in addition to the required report.

1. Anthrax*.
2. Arboviral infection.
3. Botulism*.
4. Brucellosis*.
5. Campylobacteriosis.
6. Cancer, all malignant and in situ carcinomas; in addition, all benign cancers of the central nervous system, pituitary gland, pineal gland, and craniopharyngeal duct. Carcinoma in situ of the cervix is not collected. Basal or squamous cell carcinoma is not collected unless diagnosed in the labia, clitoris, vulva, prepuce, penis, or scrotum.

7. CD4 test results (all).
8. Chickenpox (varicella).
9. Chlamydial infections.
10. Cholera*.
11. Clostridium perfringens intoxication*.
12. Coccidioidomycosis.
13. Creutzfeldt-Jakob disease.
14. Cryptosporidiosis.
15. Diphtheria*.
16. E. coli, shiga toxin-producing*.
17. Foodborne or waterborne outbreaks.
18. Giardiasis.
19. Glanders*.
20. Gonorrhea.
21. Haemophilus influenzae infection (invasive infection with haemophilus influenzae isolated from blood, cerebral spinal fluid, or other normal sterile site)*.
22. Hantavirus*.
23. Hemolytic uremic syndrome.
24. Hepatitis (A, B, C, D, and E), including hepatitis C nucleic acid test result (detectable or nondetectable) and hepatitis C genotype results.
25. Human immunodeficiency virus (HIV) infection, including acquired immunodeficiency syndrome (AIDS). (Any positive HIV test result, including gene sequencing and drug resistance patterns.) Human immunodeficiency virus (HIV) nucleic acid test result (including nondetectable).
26. Influenza.
27. Laboratory incidences involving the possible release of category A bioterrorism agents or novel influenza viruses into the laboratory environment.
28. Lead blood level results (all).
29. Legionellosis.
30. Listeriosis*.
31. Malaria*.
32. Measles (rubeola)*.
33. Melioidosis*.

34. Meningococcal disease (invasive infection with neisseria meningitidis isolated from blood, cerebral spinal fluid, or other normal sterile site)*.
35. Mumps.
36. Nipah viral infections*.
37. Nosocomial outbreaks.
38. Novel severe acute respiratory illness*.
39. Organisms resistant to carbapenem or with emerging antimicrobial resistance*.
40. Pertussis.
41. Plague*.
42. Poliomyelitis*.
43. Pregnancy in a person infected with hepatitis B or HIV.
44. Q fever*.
45. Rabies (animal or human*).
46. Rubella*.
47. Salmonellosis*.
48. Scabies outbreaks in institutions.
49. Shigellosis*.
50. Smallpox*.
51. Staphylococcus aureus, vancomycin resistant and intermediate resistant (VRSA and VISA)*.
52. Staphylococcus enterotoxin B intoxication*.
53. Streptococcus pneumoniae infections (invasive infection isolated from blood, cerebral spinal fluid, or other normal sterile site)*.
54. Syphilis.
55. Tetanus.
56. Tickborne diseases*.
57. Trichinosis.
58. Tuberculosis (tuberculosis infection caused by Mycobacterium tuberculosis or Mycobacterium bovis)*.
59. Tularemia*.
60. Tumors of the central nervous system.
61. Typhoid fever*.
62. Unexplained or emerging critical illness or death.

63. Unusual cluster of severe or unexplained illnesses or deaths.
64. Vibriosis*.
65. Viral hemorrhagic fevers.
66. Weapons of mass destruction suspected event.
67. Yellow fever*.

History: Amended effective May 1, 1984; December 1, 1986; January 1, 1988; January 1, 1989; October 1, 1990; January 1, 1991; February 1, 1992; May 1, 1994; January 1, 1995; July 1, 1996; February 1, 2000; August 1, 2002; March 1, 2003; July 1, 2004; April 1, 2007; January 1, 2011; January 1, 2018.

General Authority: NDCC 23-07-01

Law Implemented: NDCC 23-07-01